Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 6489–6491.

https://doi.org/10.1182/blood-2022-167633

Published: 2022

Journal Articles

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Blood (2022) 140 (Supplement 1): 6517–6519.

https://doi.org/10.1182/blood-2022-165419

Published: 2022

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Nicholas J Boddicker, PhD, Daniel R O'Brien, Esteban Braggio, PhD, Sara J. Achenbach, Kari G. Chaffee, MS, Aaron D. Norman, Celine M. Vachon, PhD, Brian Kabat, B.S., Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Eli Muchtar, MD, James R. Cerhan, MD PhD, Tait D. Shanafelt, MD, Neil E. Kay, MD, Neil E Caporaso, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2018-99-117044

Published: 2018

Journal Articles

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

Narjust Duma, MD, Jonas Paludo, MD, Brian Kabat, B.S., Aaron Tande, MD, Kari G Chaffee, MS, Timothy G. Call, MD, Saad Sirop Kenderian, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Melissa C. Larson, M.S., Asher A. Chanan-Khan, MD, Michael Conte, PA-C, Susan Marie Schwager, Susan L Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2017) 130 (Supplement 1): 4327.

https://doi.org/10.1182/blood.V130.Suppl_1.4327.4327

Published: 2017

Journal Articles

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Center

Paul J. Hampel, MD, Melissa C. Larson, M.S., Brian Kabat, B.S., Timothy G. Call, MD, Wei Ding, MD PhD, Saad Sirop Kenderian, MD, Michael Conte, PA-C, Susan Marie Schwager, Jose F. Leis, MD PhD, Asher A. Chanan-Khan, MD, Susan L Slager, PhD, Neil E. Kay, MD, Kari G Chaffee, MS, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2017) 130 (Supplement 1): 3023.

https://doi.org/10.1182/blood.V130.Suppl_1.3023.3023

Published: 2017

Journal Articles

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD, Tait Shanafelt

Blood (2008) 112 (11): 43.

https://doi.org/10.1182/blood.V112.11.43.43

Published: 2008

Journal Articles

Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival.

Martha Q. Lacy, MD, Sumithra Mandrekar, Brian Kabat, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, David Dingli, Mark Litzow, Peter Wettstein, S. Vincent Rajkumar, Dennis Gastineau, Morie A. Gertz, MD

Blood (2008) 112 (11): 1739.

https://doi.org/10.1182/blood.V112.11.1739.1739

Published: 2008

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Craig B. Reeder, MD, Michel K. Gornet, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Ivana N. Micallef, MD, Luis F. Porrata, MD, Patrick B. Johnston, MD, PhD, Matthew J. Maurer, MS, Betsy LaPlant, MS, Brian Kabat, MS, David J. Inwards, MD, Joseph P. Colgan, MD, Timothy Call, MD, Svetomir Markovic, MD, PhD, Clive S. Zent, MD, Steven R. Zeldenrust, MD, PhD, Han W. Tun, MD, Thomas E. Witzig, MD

Blood (2007) 110 (11): 121.

https://doi.org/10.1182/blood.V110.11.121.121

Published: 2007

Journal Articles

Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis.

Angela Dispenzieri, MD, Martha Lacy, M.D., Steven Zeldenrust, M.D., Ph.D., Suzanne R. Hayman, M.D., Shaji Kumar, M.D., Susan M. Geyer, Ph.D., John A. Lust, M.D., Ph.D., Jacob B. Allred, M.S., Thomas E. Witzig, M.D, S. Vincent Rajkumar, M.D., Philip R. Greipp, M.D., Stephen J. Russell, M.D., Ph.D., Brian Kabat, Morie Abraham Gertz, M.D.

Blood (2006) 108 (11): 130.

https://doi.org/10.1182/blood.V108.11.130.130

Published: 2006

Journal Articles

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

Angela Dispenzieri, Martha Q. Lacy, Steven R. Zeldenrust, Suzanne R. Hayman, Shaji K. Kumar, Susan M. Geyer, John A. Lust, Jacob B. Allred, Thomas E. Witzig, S. Vincent Rajkumar, Philip R. Greipp, Stephen J. Russell, Brian Kabat, Morie A. Gertz

Blood (2006) 109 (2): 465–470.

https://doi.org/10.1182/blood-2006-07-032987

Published: 2006

Journal Articles

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

S. Vincent Rajkumar, Suzanne R. Hayman, Martha Q. Lacy, Angela Dispenzieri, Susan M. Geyer, Brian Kabat, Steven R. Zeldenrust, Shaji Kumar, Philip R. Greipp, Rafael Fonseca, John A. Lust, Stephen J. Russell, Robert A. Kyle, Thomas E. Witzig, Morie A. Gertz

Blood (2005) 106 (13): 4050–4053.

https://doi.org/10.1182/blood-2005-07-2817

Published: 2005

Journal Articles

Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.

S. Vincent Rajkumar, MD, Suzanne Hayman, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Susan M. Geyer, PhD, Brian Kabat, Steven R. Zeldenrust, MD, PhD, Shaji Kumar, MD, Philip R. Greipp, MD, Rafael Fonseca, MD, John A. Lust, MD, PhD, Stephen J. Russell, MD, PhD, Robert A. Kyle, MD, Thomas E. Witzig, MD, Morie A. Gertz, MD

Blood (2005) 106 (11): 781.

https://doi.org/10.1182/blood.V106.11.781.781

Published: 2005

Journal Articles

Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.

Angela Dispenzieri, MD, Martha Q. Lacy, MD, Steven R. Zeldenrust, MD, PhD, Susan M. Geyer, PhD, John A. Lust, MD, PhD, Suzanne R. Hayman, MD, Shaji K. Kumar, MD, Jacob B. Allred, S. Vincent Rajkumar, MD, Brian Kabat, Thomas E. Witzig, MD, Philip R. Greipp, MD, Steven R. Russell, MD, PhD, Irene Ghobrial, MD, Morie A. Gertz, MD

Blood (2005) 106 (11): 252.

https://doi.org/10.1182/blood.V106.11.252.252

Published: 2005

Journal Articles

Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Stephanie Fink, Susan Geyer, Ph.D., Tait Shanafelt, M.D., Stephanie Smoley, Sarah Paternoster, Karin Giordano, Renee Tschumper, Diane Jelinkek, Ph.D., Nancy Bone, Brian Kabat, Timothy Call, M.D., Robert Phyliky, M.D., Neil Kay, M.D., Gordon Dewald, Ph.D

Blood (2004) 104 (11): 2799.

https://doi.org/10.1182/blood.V104.11.2799.2799

Published: 2004

NARROW

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Center

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis.

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.

Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.

Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only